PDCD1 and neoplasm: These inhibitors work by attaching to protein receptors on the surface of T cells, which activates T cell-mediated immune responses, blocking the PD-L1/PD-1 inhibitory signaling pathway, and enhancing the body’s anti-tumor immune response (15, 16).